department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zegfrovy · pharmadog

pharmadog
drugs
Zegfrovy

drug · small molecule

patient view →

sunvozertinib

Marketedupdated 2mo ago

by Dizal Pharmaceutical Co Ltd🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.

indications

investigational

NSCLC

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Zegfrovy

generic

sunvozertinib

indication

Non-Small Cell Lung Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 2, 2030

~4.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Jan 28, 2039compositionUS 11007198
Jan 28, 2039compositionUS 11007198
Jan 28, 2039compositionUS 11504375
Jan 28, 2039compositionUS 11504375
Jan 28, 2039compositionUS 11896597
Jan 28, 2039compositionUS 11896597

FDA exclusivities (2)

Jul 2, 2030NCENew Chemical Entity (5y)4.0y
Jul 2, 2030NCENew Chemical Entity (5y)4.0y

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying sunvozertinib

phase1A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)recruitingn=140
phase3A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)active not recruitingn=324
phase2Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)active not recruitingn=315
phase2Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)recruitingn=200
phase3A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgeryrecruitingn=360
phase2Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCrecruitingn=27
phase2Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)active not recruitingn=104